Born Deaf No More: FDA Greenlights Historic Treatment

Regeneron's Otarmeni restores hearing in children born with a rare genetic form of deafness and it won't cost patients a cent

13 May 2026

Fifty newborns in America each year enter the world unable to hear, not from damage, but from a faulty gene. For most of their lives, the standard remedy has been a cochlear implant: a device that mimics hearing without addressing its absence. That distinction now matters more than before.

Regeneron's Otarmeni has received FDA accelerated approval as the first gene therapy for hearing loss caused by variants in the OTOF gene. Rather than routing around the problem, it corrects it: a single infusion into the inner ear delivers a working copy of the OTOF gene, allowing hair cells to produce otoferlin, a protein that carries sound signals to the auditory nerve. No prior treatment has addressed the condition at this level.

Clinical evidence is modest but real. In the CHORD Phase 1/2 trial, 80% of treated participants showed meaningful hearing improvement within 24 weeks. With longer follow-up, 42% reached thresholds consistent with normal hearing, including the ability to detect whispered speech. Approval arrived 61 days after filing, under a new framework, the National Priority Voucher pilot programme, designed to fast-track genuinely transformative therapies.

More striking is Regeneron's commercial decision. Gene therapies for rare diseases typically carry seven-figure price tags; Otarmeni will be offered at no cost to eligible patients in America. Surgical costs for the infusion procedure remain the patient's responsibility, but that is not a price wall.

A quieter problem persists. OTOF-related deafness is regularly missed because genetic testing after a hearing diagnosis is not standard. Researchers involved in the CHORD trial expect the approval to push hospitals toward broader screening, expanding the number of children who can benefit. Whether health systems act on that expectation is a policy question the therapy alone cannot answer.

Eli Lilly's $1.12 billion commitment earlier this year to a gene-editing platform for hereditary deafness signals sharpening commercial interest in the field. Welcome, provided it extends access rather than merely valuing the underlying science.